Condition
CD7+ Lymphoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Not Yet Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07117305Phase 1Not Yet RecruitingPrimary
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
NCT07008872Not ApplicableNot Yet RecruitingPrimary
CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia
NCT04599556Phase 1Unknown
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
Showing all 3 trials